Moving Medicines
to Move People

Reneo is focused on improving the lives of patients with rare genetic mitochondrial diseases.

Our priority is to develop therapies to improve daily function and quality of life of patients living with these rare diseases.

Reneo’s lead product candidate, mavodelpar (REN001), is known to control a number of genes involved in mitochondrial function.